Taysha Gene Therapies to Host First Annual Stockholder Meeting

Rhea-AI Summary

Taysha Gene Therapies (Nasdaq: TSHA) announced its first annual stockholder meeting will take place on June 17, 2021, at 10 am ET via webcast. The meeting can be accessed through the company’s corporate website. Taysha focuses on developing AAV-based gene therapies for monogenic diseases affecting the central nervous system, with a commitment to translating therapies from bench to bedside. Their integrated approach aims to improve patient lives through innovative treatments.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its first annual stockholder meeting will be held June 17, 2021 at 10 am ET via webcast.

The webcast for this meeting will be available in the “Events & Presentations” section of the Taysha corporate website. A copy of Taysha’s 2020 annual report is available here and in the “Financial Information” section of the Taysha Corporate Website.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210610005302/en/

FAQ

What is the date of Taysha Gene Therapies' first annual stockholder meeting?

The first annual stockholder meeting of Taysha Gene Therapies will be held on June 17, 2021.

How can I access the Taysha Gene Therapies stockholder meeting?

The stockholder meeting can be accessed via webcast on Taysha's corporate website.

What is Taysha Gene Therapies focused on?

Taysha Gene Therapies is focused on developing AAV-based gene therapies for monogenic diseases of the central nervous system.

What time will the Taysha stockholder meeting start?

The Taysha stockholder meeting will start at 10 am ET.

Where can I find Taysha Gene Therapies' 2020 annual report?

Taysha's 2020 annual report is available on their corporate website in the 'Financial Information' section.